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COCAINE HYDROLASE-FC FUSION 
PROTEINS FOR COCAINE AND METHODS 
FOR UTILIZING THE SAME 
RELATED APPLICATIONS 
This application claims priority from U.S. Provisional 
Patent Application No. 61/735,719, filed Dec. 11, 2012, the 




This invention was made with govermnent support under 
15 
Grant Numbers R01DA013930, R01DA035552, and 
R01DA032910 awarded by the National Institute on Drug 
Abuse (NIDA) of the National Institutes of Health (NIH). 
The government has certain rights in the invention. 
20 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to polypep-
tides comprising butyrylcholinesterase (BChE) and one or 
more other polypeptides. In particular, the presently-dis- 25 
closed subject matter relates to isolated polypeptides com-
prising a BChE variant and a second polypeptide variant. 
INTRODUCTION 
Cocaine abuse is a major medical and public health 
problem that continues to defy treatment. The disastrous 
medical and social consequences of cocaine addiction, such 
30 
as violent crime, loss in individual productivity, illness, and 
death, have made the development of an effective pharma- 35 
cological treatment a high priority. However, cocaine medi-
ates its reinforcing and toxic effects by blocking neurotrans-
mitter reuptake and the classical pharmacodynamic 
approach has failed to yield small-molecule receptor antago-
nists due to the difficulties inherent in blocking a blocker. An 40 
alternative to receptor-based approaches is to interfere with 
the delivery of cocaine to its receptors and accelerate its 
metabolism in the body. 
The dominant pathway for cocaine metabolism in pri-
mates is butyrylcholinesterase (BChE)-catalyzed hydrolysis 45 
at the benzoyl ester group (Scheme 1). 
BChE -
(+)-cocaine 
Only 5% of the cocaine is deactivated through oxidation 
by the liver microsomal cytochrome P450 system. Cocaine 
hydrolysis at benzoyl ester group yields ecgonine methyl 
ester, whereas the oxidation produces norcocaine. The 
metabolite ecgonine methyl ester is a biologically inactive 
metabolite, whereas the metabolite norcocaine is hepato-
toxic and a local anesthetic. BChE is synthesized in the liver 
and widely distributed in the body, including plasma, brain, 
and lung. Extensive experimental studies in animals and 
humans demonstrate that enhancement of BChE activity by 
administration of exogenous enzyme substantially decreases 
cocaine half-life. 
Enhancement of cocaine metabolism by administration of Scheme 1. Schematic representation of BChE-catalyzed hydrolysis at the 
benzoyl ester group. 
50 BChE has been recognized to be a promising pharmacoki-
netic approach for treatment of cocaine abuse and depen-
dence. However, the catalytic activity of this plasma enzyme 
is three orders-of-magnitude lower against the naturally 
occurring ( - )-cocaine than that against the biologically 
BChE -
(-)-cocaine 
55 inactive (+)-cocaine enantiomer. (+)-cocaine can be cleared 
from plasma in seconds and prior to partitioning into the 
central nervous system (CNS), whereas (-)-cocaine has a 
plasma half-life of approximately 45-90 minutes (for a 
relatively low dose of cocaine), long enough for manifesta-
60 tion of the CNS effects which peak in minutes. Under the 
overdose condition, BChE is saturated with ( - )-cocaine and, 
thus, the plasma half-life of (-)-cocaine will be longer. 
Furthermore, recombinant human BChE is quickly elimi-
nated from the circulation relative to native human BChE 
65 that can be purified from human plasma. For instance, it has 
been observed that recombinant human BChE only has a 
relatively short half-life of about 15 minutes to about 8 hours 
US 10,772,940 Bl 
3 
in humans. Therefore, while known recombinant human 
BChE may be suitable for administration over shorter time 
periods, which can be the case when seeking overdose relief, 
recombinant BChE less desirable for rehabilitation and other 
treatments, which are best accomplished with more consis- 5 
tent doses of BChE that administered over relatively longer 
time periods. Without being bound by theory or mechanism, 
these differences in half-life between known recombinant 
human BChE and native human BChE is caused by particu-
lar posttranslational modifications of native human BChE, 10 
including oligomerization and glycosylation. 
Hence, BChE mutants with high activity against ( - )-
cocaine are highly desired for use in humans. BChE mutants 
having a relatively longer half-life are also highly desired, 
15 
particularly for use in cocaine rehabilitation treatments and 
the like. 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the above-identified needs, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
20 
This S=ary describes several embodiments of the 25 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea-
tures of a given embodiment is likewise exemplary. Such an 30 
embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this Summary or not. To avoid 
excessive repetition, this Summary does not list or suggest 35 
all possible combinations of such features. 
The presently-disclosed subject matter includes an iso-
lated polypeptide comprising a butyrylcholinesterase 
(BChE) polypeptide and a second polypeptide. In some 
embodiments the BChE polypeptide is a BChE polypeptide 40 
variant that comprises an amino acid sequence selected from 
SEQ ID NOS: 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 
50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 
82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 
110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 45 
and 134 as set forth herein. In some embodiments the 
provided BChE polypeptide is a BChE polypeptide frag-
ment. Also, in some embodiments the second polypeptide is 
a second polypeptide variant comprising an amino acid 
sequence selected from SEQ ID NOS: 6, 8, 10, 12, 14, 16, 50 
18, 20, 22, and 24, as set forth herein. In some embodiments 
the provided second polypeptide is a second polypeptide 
fragment. 
The presently-disclosed subject matter further includes 
isolated nucleic acid molecules that encode an isolated 55 
polypeptide that comprises a BChE polypeptide and a sec-
ond polypeptide. In some embodiments the nucleic acid 
sequence encodes a BChE polypeptide variant, and the 
nucleic acid sequence is selected from SEQ ID NOS: 25, 27, 
29,31, 33,35,37, 39, 41,43,45, 47,49, 51, 53, 55, 57, 59, 60 
61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 
93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 
119, 121, 123, 125, 127, 129, 131, and 133, as set forth 
herein. Also, in some embodiments the nucleic acid 
sequence encodes a second polypeptide variant, and the 65 
nucleic acid sequence is selected from SEQ ID NOS: 5, 7, 
9, 11, 13, 15, 17, 19, 21, and 23, as set forth herein. 
4 
Still further, in some embodiments of the isolated poly-
peptide there is provided a linker disposed between the 
BChE polypeptide and the second polypeptide. In some 
embodiments the linker comprises about 1 to about 7 amino 
acids. 
The presently-disclosed subject matter also comprises a 
pharmaceutical composition that includes an isolated poly-
peptide, which includes a BChE polypeptide and a second 
polypeptide, or variants and/or fragments thereof, as well as 
a suitable pharmaceutical carrier. 
The presently-disclosed subject matter further includes a 
method of treating a cocaine-induced condition, which 
includes administering to an individual an effective amount 
of an isolated polypeptide or a pharmaceutical composition 
comprising an isolated polypeptide, as described herein, to 
lower blood cocaine concentration in a subject. In some 
embodiments, the isolated polypeptide has a biological 
half-life of about 4 days to about 40 days in humans. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 includes a chart showing the catalytic activity(%) 
240 hours after administration of an isolated polypeptide 
including a BChE polypeptide variant (SEQ ID NO: 48) 
fused to a second polypeptide variant (SEQ ID NO: 6). No 
linker is included in this isolated polypeptide. The isolated 
polypeptide has a SEQ ID NO: 156, which includes a 
fragment having amino acids 1-529 and the following amino 
acid substitutions, as compared to wild type BChE: Al 99S, 
F227 A, S287G, A328W, and Y332G (SEQ ID NO: 48), and 
a second polypeptide variant having the following amino 
acid substitutions, as compared to wild type second poly-
peptide: AlV, D142E, and L144M (SEQ ID NO: 6). Rat 
blood samples were collected from animals at various time 
points after the fusion protein injection. Then the enzyme 
activity of the serum against cocaine was measured in vitro. 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTING 
SEQ ID NO: 1 is a nucleotide sequence encoding a wild 
type second polypeptide of SEQ ID NO: 2; 
SEQ ID NO: 2 is an amino acid sequence encoding a wild 
type second polypeptide; 
SEQ ID NO: 3 is a nucleotide sequence encoding a wild 
type second polypeptide fragment of SEQ ID NO: 4; 
SEQ ID NO: 4 is an amino acid sequence encoding a wild 
type second polypeptide fragment polypeptide wherein 16 
amino acid residues are deleted from the N-terminus; 
SEQ ID NO: 5 is a nucleotide sequence encoding a second 
polypeptide variant of SEQ ID NO: 6; 
SEQ ID NO: 6 is an amino acid sequence encoding a 
second polypeptide variant having the following amino acid 
substitutions, as compared to wild type second polypeptide: 
AlV, D142E, and L144M; 
SEQ ID NO: 7 is a nucleotide sequence encoding a second 
polypeptide variant of SEQ ID NO: 8; 
SEQ ID NO: 8 is an amino acid sequence encoding a 
second polypeptide variant having the following amino acid 
substitutions, as compared to wild type second polypeptide: 
AlV, E58Q, E69Q, E80Q, D98N, NlOlD, D142E, and 
L144M; 
SEQ ID NO: 9 is a nucleotide sequence encoding a second 
polypeptide variant of SEQ ID NO: 1 O; 
SEQ ID NO: 10 is an amino acid sequence encoding a 
second polypeptide variant having the following amino acid 
US 10,772,940 Bl 
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substitutions, as compared to wild type second polypeptide: 
AlQ, C6S, C12S, C15S, and P24S; 
SEQ ID NO: 11 is a nucleotide sequence encoding a 
second polypeptide variant of SEQ ID NO: 12; 
SEQ ID NO: 12 is an amino acid sequence encoding a 5 
second polypeptide variant having the following amino acid 
substitutions, as compared to wild type second polypeptide: 
AlV, M38Y, D142E, and L144M; 
6 
SEQ ID NO: 33 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 34; 
SEQ ID NO: 34 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227 A, A328W, and Y332G; 
SEQ ID NO: 13 is a nucleotide sequence encoding a 
second polypeptide variant of SEQ ID NO: 14; 
SEQ ID NO: 14 is an amino acid sequence encoding a 
second polypeptide variant having the following amino acid 
substitutions, as compared to wild type second polypeptide: 
AlV, T42E, D142E, and L144M; 
SEQ ID NO: 35 is a nucleotide sequence encoding a 
BChE polypeptide variant and fragment of SEQ ID NO: 36; 
SEQ ID NO: 36 is an amino acid sequence encoding a 
10 BChE polypeptide variant and fragment having amino acids 
1-531 and the following amino acid substitutions, as com-
pared to wild type BChE: Al 99S, F227 A, A328W, and 
Y332G; 
SEQ ID NO: 15 is a nucleotide sequence encoding a 15 
second polypeptide variant of SEQ ID NO: 16; 
SEQ ID NO: 37 is a nucleotide sequence encoding a 
BChE polypeptide variant and fragment of SEQ ID NO: 38; 
SEQ ID NO: 38 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 
1-529 and the following amino acid substitutions, as com-
20 pared to wild type BChE: Al 99S, F227 A, A328W, and 
Y332G; 
SEQ ID NO: 16 is an amino acid sequence encoding a 
second polypeptide variant having the following amino acid 
substitutions, as compared to wild type second polypeptide: 
AlV, M38Y, S40T, D142E, and L144M; 
SEQ ID NO: 17 is a nucleotide sequence encoding a 
second polypeptide variant of SEQ ID NO: 18; 
SEQ ID NO: 18 is an amino acid sequence encoding a 
second polypeptide variant having the following amino acid 
substitutions, as compared to wild type second polypeptide: 25 
AlV, M38Y, S40T, T42E, D142E, and L144M; 
SEQ ID NO: 19 is a nucleotide sequence encoding a 
second polypeptide variant of SEQ ID NO: 20; 
SEQ ID NO: 20 is an amino acid sequence encoding a 
second polypeptide variant having the following amino acid 30 
substitutions, as compared to wild type second polypeptide: 
AlQ, C6S, C12S, C15S, P24S, and M38Y; 
SEQ ID NO: 21 is a nucleotide sequence encoding a 
second polypeptide variant of SEQ ID NO: 22; 
SEQ ID NO: 39 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 40; 
SEQ ID NO: 40 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
S287G, A328W, and Y332G; 
SEQ ID NO: 41 is a nucleotide sequence encoding a 
BChE polypeptide variant and fragment of SEQ ID NO: 42; 
SEQ ID NO: 42 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 
1-531 and the following amino acid substitutions, as com-
pared to wild type BChE: Al 99S, S287G, A328W, and 
Y332G; 
SEQ ID NO: 22 is an amino acid sequence encoding a 35 
second polypeptide variant having the following amino acid 
substitutions, as compared to wild type second polypeptide: 
SEQ ID NO: 43 is a nucleotide sequence encoding a 
BChE polypeptide variant and fragment of SEQ ID NO: 44; 
SEQ ID NO: 44 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 
1-529 and the following amino acid substitutions, as com-
40 pared to wild type BChE: Al 99S, S287G, A328W, and 
Y332G; 
AlQ, C6S, C12S, C15S, P24S, M38Y, and S40T. 
SEQ ID NO: 23 is a nucleotide sequence encoding a 
second polypeptide variant of SEQ ID NO: 24; 
SEQ ID NO: 24 is an amino acid sequence encoding a 
second polypeptide variant having the following amino acid 
substitutions, as compared to wild type second polypeptide: 
AlQ, C6S, C12S, C15S, P24S, M38Y, S40T, and T42E. 
SEQ ID NO: 25 is a nucleotide sequence encoding a wild 45 
type butyrylcholinesterase (BChE) polypeptide of SEQ ID 
NO: 26; 
SEQ ID NO: 26 is an amino acid sequence encoding a 
wild type BChE polypeptide; 
SEQ ID NO: 27 is a nucleotide sequence encoding a 50 
BChE polypeptide variant of SEQ ID NO: 28; 
SEQ ID NO: 28 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
A328W, and Y332G; 
SEQ ID NO: 29 is a nucleotide sequence encoding a 
BChE polypeptide variant and fragment of SEQ ID NO: 30; 
55 
SEQ ID NO: 30 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 
1-531 and the following amino acid substitutions, as com- 60 
pared to wild type BChE: A199S, A328W, and Y332G; 
SEQ ID NO: 31 is a nucleotide sequence encoding a 
BChE polypeptide variant and fragment of SEQ ID NO: 32; 
SEQ ID NO: 32 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 65 
1-529 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, A328W, and Y332G; 
SEQ ID NO: 45 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 46; 
SEQ ID NO: 46 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227 A, S287G, A328W, and Y332G; 
SEQ ID NO: 47 is a nucleotide sequence encoding a 
BChE polypeptide variant and fragment of SEQ ID NO: 48; 
SEQ ID NO: 48 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 
1-531 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
and Y332G; 
SEQ ID NO: 49 is a nucleotide sequence encoding a 
BChE polypeptide variant and fragment of SEQ ID NO: 50; 
SEQ ID NO: 50 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 
1-529 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
and Y332G; 
SEQ ID NO: 51 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 52; 
SEQ ID NO: 52 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227A, S287G, A328W, and E441D; 
US 10,772,940 Bl 
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SEQ ID NO: 53 is a nucleotide sequence encoding a 
BChE polypeptide variant and fragment of SEQ ID NO: 54; 
8 
substitutions, as compared to wild type BChE: Al 99S, 
F227G, S287G, A328W, and Y332G; 
SEQ ID NO: 54 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 
1-531 and the following amino acid substitutions, as com- 5 
pared to wild type BChE: A199S, F227A, S287G, A328W, 
and E441D; 
SEQ ID NO: 75 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 76; 
SEQ ID NO: 76 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
P285S, S287G, A328W, and Y332G; SEQ ID NO: 55 is a nucleotide sequence encoding a 
BChE polypeptide variant and fragment of SEQ ID NO: 56; SEQ ID NO: 77 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 78; 
SEQ ID NO: 78 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
SEQ ID NO: 56 is an amino acid sequence encoding a 10 
BChE polypeptide variant and fragment having amino acids 
1-529 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
and E441D; 
15 
F227V, S287G, A328W, and Y332G; 
SEQ ID NO: 57 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 58; 
SEQ ID NO: 58 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227 A, P285A, S287G, A328W, and Y332G; 
SEQ ID NO: 59 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 60; 
SEQ ID NO: 60 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227 A, P285S, S287G, A328W, and Y332G; 
SEQ ID NO: 61 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 62; 
SEQ ID NO: 79 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 80; 
SEQ ID NO: 80 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
20 substitutions, as compared to wild type BChE: Al 99S, 
P285G, S287G, A328W, and Y332G; 
SEQ ID NO: 81 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 82; 
SEQ ID NO: 82 is an amino acid sequence encoding a 
25 BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227I, S287G, A328W, and Y332G; 
SEQ ID NO: 83 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 84; 
SEQ ID NO: 62 is an amino acid sequence encoding a 30 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227 A, P285Q, S287G, A328W, and Y332G; 
SEQ ID NO: 84 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227L, S287G, A328W, and Y332G; 
SEQ ID NO: 63 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 64; 
SEQ ID NO: 64 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227P, S287G, A328W, and Y332G; 
SEQ ID NO: 85 is a nucleotide sequence encoding a 
35 BChE polypeptide variant of SEQ ID NO: 86; 
SEQ ID NO: 86 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
L286M, S287G, A328W, and Y332G; 
SEQ ID NO: 65 is a nucleotide sequence encoding a 40 
BChE polypeptide variant of SEQ ID NO: 66; 
SEQ ID NO: 87 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 88; 
SEQ ID NO: 66 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227 A, P285G, S287G, A328W, and Y332G; 
SEQ ID NO: 67 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 68; 
SEQ ID NO: 68 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227 A, L286M, S287G, A328W, and Y332G; 
SEQ ID NO: 69 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 70; 
SEQ ID NO: 70 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
P285Q, S287G, A328W, and Y332G; 
SEQ ID NO: 71 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 72; 
SEQ ID NO: 88 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
45 F227 A, P285K, S287G, A328W, and Y332G; 
SEQ ID NO: 89 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 90; 
SEQ ID NO: 90 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
50 substitutions, as compared to wild type BChE: Al 99S, 
F227S, S287G, A328W, and Y332G; 
SEQ ID NO: 91 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 92; 
SEQ ID NO: 92 is an amino acid sequence encoding a 
55 BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227T, S287G, A328W, and Y332G; 
SEQ ID NO: 93 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 94; 
SEQ ID NO: 72 is an amino acid sequence encoding a 60 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
P285I, S287G, A328W, and Y332G; 
SEQ ID NO: 94 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227M, S287G, A328W, and Y332G; 
SEQ ID NO: 73 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 74; 
SEQ ID NO: 74 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
SEQ ID NO: 95 is a nucleotide sequence encoding a 
65 BChE polypeptide variant of SEQ ID NO: 96; 
SEQ ID NO: 96 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
US 10,772,940 Bl 
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substitutions, as compared to wild type BChE: Al 99S, 
F227C, S287G, A328W, and Y332G; 
SEQ ID NO: 97 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 98; 
10 
substitutions, as compared to wild type BChE: Al 99S, 
F227G, P285G, S287G, A328W, and Y332G; 
SEQ ID NO: 119 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 120; 
SEQ ID NO: 120 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227G, P285Q, S287G, A328W, and Y332G; 
SEQ ID NO: 98 is an amino acid sequence encoding a 5 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227 A, P285N, S287G, A328W, and Y332G; 
SEQ ID NO: 121 is a nucleotide sequence encoding a 
10 BChE polypeptide variant of SEQ ID NO: 122; 
SEQ ID NO: 99 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 100; 
SEQ ID NO: 100 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227P, P285A, S287G, A328W, and Y332G; 
SEQ ID NO: 101 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 102; 
SEQ ID NO: 102 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227S, P285Q, S287G, A328W, and Y332G; 
SEQ ID NO: 103 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 104; 
SEQ ID NO: 104 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227S, P285S, S287G, A328W, and Y332G; 
SEQ ID NO: 105 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 106; 
SEQ ID NO: 106 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227S, P285G, S287G, A328W, and Y332G; 
SEQ ID NO: 107 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 108; 
SEQ ID NO: 108 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227P, P285S, L286M, S287G, A328W, and Y332G; 
SEQ ID NO: 109 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 11 O; 
SEQ ID NO: 110 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227A, P285S, S287G, A328W, and E441D; 
SEQ ID NO: 111 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 112; 
SEQ ID NO: 112 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227A, P285A, S287G, A328W, and E441D; 
SEQ ID NO: 113 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 114; 
SEQ ID NO: 114 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227P, L286M, S287G, A328W, and Y332G; 
SEQ ID NO: 115 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 116; 
SEQ ID NO: 116 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227G, P285A, S287G, A328W, and Y332G; 
SEQ ID NO: 117 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 118; 
SEQ ID NO: 118 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
15 
SEQ ID NO: 122 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227G, P285S, S287G, A328W, and Y332G; 
SEQ ID NO: 123 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 124; 
SEQ ID NO: 124 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
20 F227 A, P285E, S287G, A328W, and Y332G; 
SEQ ID NO: 125 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 126; 
SEQ ID NO: 126 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
25 substitutions, as compared to wild type BChE: Al 99S, 
F227P, P285N, S287G, A328W, and Y332G; 
SEQ ID NO: 127 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 128; 
SEQ ID NO: 128 is an amino acid sequence encoding a 
30 BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227S, P285A, S287G, A328W, and Y332G; 
35 
SEQ ID NO: 129 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 130; 
SEQ ID NO: 130 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227S, P285N, S287G, A328W, and Y332G; 
SEQ ID NO: 131 is a nucleotide sequence encoding a 
40 BChE polypeptide variant of SEQ ID NO: 132; 
45 
SEQ ID NO: 132 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
F227S, L286M, S287G, A328W, and Y332G; 
SEQ ID NO: 133 is a nucleotide sequence encoding a 
BChE polypeptide variant of SEQ ID NO: 134; 
SEQ ID NO: 134 is an amino acid sequence encoding a 
BChE polypeptide variant having the following amino acid 
substitutions, as compared to wild type BChE: Al 99S, 
50 F227G, L286M, S287G, A328W, and Y332G. 
SEQ ID NO: 135 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 
1-530 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
55 and Y332G; 
SEQ ID NO: 136 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 
1-532 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
60 and Y332G; 
SEQ ID NO: 137 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 
1-533 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
65 and Y332G; 
SEQ ID NO: 138 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 
US 10,772,940 Bl 
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1-534 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
and Y332G; 
SEQ ID NO: 139 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 5 
1-535 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
and Y332G; 
SEQ ID NO: 140 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 10 
1-536 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
and Y332G; 
SEQ ID NO: 141 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 15 
1-537 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
and Y332G; 
SEQ ID NO: 142 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 20 
1-538 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
and Y332G; 
SEQ ID NO: 143 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 25 
1-539 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
and Y332G; 
SEQ ID NO: 144 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 30 
1-540 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, S287G, A328W, 
and Y332G; 
SEQ ID NO: 145 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 35 
1-529 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, P285Q, S287G, 
A328W, and Y332G; 
SEQ ID NO: 146 is an amino acid sequence encoding a 
BChE polypeptide variant and fragment having amino acids 40 
1-536 and the following amino acid substitutions, as com-
pared to wild type BChE: A199S, F227A, P285Q, S287G, 
A328W, and Y332G; 
SEQ ID NO: 147 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 45 
50, a linker having the amino acid sequence GGGGGGS, 
and a second polypeptide sequence of SEQ ID NO: 4; 
SEQ ID NO: 148 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50 and a second polypeptide sequence of SEQ ID NO: 2; 50 
SEQ ID NO: 149 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
46, a linker having the amino acid sequence GGGGGGS, 
and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 150 is an amino acid sequence encoding a 55 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
46 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 151 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50, a linker having the amino acid sequence GGGGGGS, 60 
and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 152 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 153 is an amino acid sequence encoding a 65 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50 and a second polypeptide sequence of SEQ ID NO: 8; 
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SEQ ID NO: 154 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50 and a second polypeptide sequence of SEQ ID NO: 1 0; 
SEQ ID NO: 155 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
135 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 156 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
46 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 157 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
136 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 158 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
137 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 159 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
138 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 160 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
139 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 161 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
140 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 162 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
141 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 163 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
142 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 164 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
143 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 165 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
144 and a second polypeptide sequence of SEQ ID NO: 6; 
SEQ ID NO: 166 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50 and a second polypeptide sequence of SEQ ID NO: 12; 
SEQ ID NO: 167 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50 and a second polypeptide sequence of SEQ ID NO: 14; 
SEQ ID NO: 168 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50 and a second polypeptide sequence of SEQ ID NO: 16; 
SEQ ID NO: 169 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50 and a second polypeptide sequence of SEQ ID NO: 18; 
SEQ ID NO: 170 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
137 and a second polypeptide sequence of SEQ ID NO: 18; 
SEQ ID NO: 171 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
140 and a second polypeptide sequence of SEQ ID NO: 18; 
SEQ ID NO: 172 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50 and a second polypeptide sequence of SEQ ID NO: 20; 
SEQ ID NO: 173 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50 and a second polypeptide sequence of SEQ ID NO: 22; 
SEQ ID NO: 174 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
50 and a second polypeptide sequence of SEQ ID NO: 24; 
SEQ ID NO: 175 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
137 and a second polypeptide sequence of SEQ ID NO: 24; 
US 10,772,940 Bl 
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SEQ ID NO: 176 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
140 and a second polypeptide sequence of SEQ ID NO: 24; 
SEQ ID NO: 177 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 5 
145 and a second polypeptide sequence of SEQ ID NO: 6; 
and 
14 
cocaine, including, for example, overdose and treatment for 
an addiction to cocaine. For example, a polypeptide or 
nucleotide, as described herein, could be administered prior 
to the use of cocaine as part of an addiction treatment 
strategy ( e.g., rehabilitation). 
The term "isolated", when used in the context of an 
isolated nucleotide or an isolated polypeptide, is a nucleo-
tide or polypeptide that, by the hand of man, exists apart 
from its native environment and is therefore not a product of 
SEQ ID NO: 178 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID NO: 
146 and a second polypeptide sequence of SEQ ID NO: 18. 
SEQ ID NO: 179 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID 
NO:62 and a second polypeptide sequence of SEQ ID NO: 
12. 
10 nature. An isolated nucleotide or polypeptide can exist in a 
purified form or can exist in a non-native environment such 
as, for example, in a transgenic host cell. 
In some embodiments, the isolated polypeptide comprises 
a BChE polypeptide variant and/or fragment. For example, 
SEQ ID NO: 180 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID 
NO:62 and a second polypeptide sequence of SEQ ID NO: 
18. 
SEQ ID NO: 181 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID 
NO:58 and a second polypeptide sequence of SEQ ID NO: 
12. 
15 a BChE polypeptide variant can comprise a wild type BChE 
polypeptide having one to ten or more amino acid substi-
tutions selectedfromA199S, F227A, F227C, F227G, F227I, 
F227L, F227M, F227P, F227S, F227T, F227V, P285A, 
P285E, P285G, P285I, P285K, P285N, P285Q, P285S, 
SEQ ID NO: 182 is an amino acid sequence encoding a 
polypeptide comprising a BChE polypeptide of SEQ ID 
NO:58 and a second polypeptide sequence of SEQ ID NO: 
18. 
20 L286M, S287G, A328W, Y332G, and E441D. In some 
embodiments, the particular BChE polypeptide variants 
exhibit increased catalytic efficiency against ( - )-cocaine 
compared to wild type BChE polypeptides. 
The terms "polypeptide", "protein", and "peptide", which 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
25 are used interchangeably herein, refer to a polymer of the 
protein amino acids, or amino acid analogs, regardless of its 
size or function. Although "protein" is often used in refer-
ence to relatively large polypeptides, and "peptide" is often 
used in reference to small polypeptides, usage of these terms 
30 in the art overlaps and varies. The term "polypeptide" as 
used herein refers to peptides, polypeptides, and proteins, 
unless otherwise noted. The terms "protein", "polypeptide", 
and "peptide" are used interchangeably herein when refer-
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 35 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 40 
this document, including definitions, will control. 
The presently-disclosed subject matter includes an iso-
lated polypeptide that comprises a butyrylcholinesterase 
(BChE) polypeptide, or variants and/or fragments thereof, 
and a second polypeptide, or variants and/or fragments 45 
thereof. The isolated polypeptides disclosed herein have 
enhanced catalytic efficiency for (-)-cocaine, as compared to 
wild type BChE. Furthermore, the isolated polypeptides 
comprising BChE, or variants and/or fragments thereof, 
disclosed herein can also have a longer half-life in blood 50 
than BChE polypeptides alone. Exemplary BChE polypep-
tides, including fragments and/or variants thereof, include 
those shown in U.S. Pat. Nos. 8,592,193, 8,206,703, 8,193, 
327, 7,919,082, 7,892,537, 7,740,840, 7,731,957, and 7,438, 
904, all of which are incorporated herein by this reference in 55 
their entirety. 
The presently-disclosed subject matter further includes a 
pharmaceutical composition including an isolated polypep-
tide, as described herein, and a suitable pharmaceutical 
carrier. The presently-disclosed subject matter further 60 
includes a method for treating a cocaine-induced condition 
in a subject comprising administering to an individual an 
effective amount of an isolated polypeptide and/or an iso-
lated nucleotide (i.e., a nucleotide molecule encoding an 
isolated polypeptide, as disclosed herein) to lower blood 65 
cocaine concentration in the subject. A cocaine-induced 
condition resulting from the administration and/or use of 
ring to a gene product. Thus, exemplary polypeptides 
include gene products, naturally occurring proteins, 
homologs, orthologs, paralogs, fragments and other equiva-
lents, variants, and analogs of the foregoing. Furthermore, 
the term "fusion polypeptide" is used herein to generally 
refer to a polypeptide formed from two or more distinct 
polypeptides. 
The term "variant" refers to an amino acid sequence that 
is different from the reference polypeptide by one or more 
amino acids, e.g., one or more amino acid substitutions. For 
example a butyrylcholinesterase (BChE) polypeptide variant 
differs from wild-type BChE (SEQ ID NO: 26) by one or 
more amino acid substitutions, i.e., mutations. An example 
of a BChE variant is shown as SEQ ID NO: 28. Another 
example of a BChE variant includes a sequence that O to 
about 41 amino acid residues are deleted from the N-termi-
nus, and O to about 98 amino acid residues are deleted from 
the C-terminus of the wild-type BChE. Another example of 
a BChE variant includes one, two, three, four, five six, 
seven, or eight substitutions relative to wild-type BChE 
(SEQ ID NO: 26) at A199, F227, P285, L286, S287, A328, 
Y332, and/or E441, in particular, the variant comprises one 
to eight amino acid mutations relative to SEQ ID NO:26 
selected from A199S, F227A, F227C, F227G, F227I, 
F227M, F227P, F227S, F227T, or F227V; P285A, P285E, 
P285G, P285I, P285K, P285N, P285Q, or P285S; L286M; 
5287G; A328W; Y332G, and E441D. 
In some embodiments, the BChE polypeptide is a frag-
ment of a wild type BChE polypeptide. In some embodi-














569, 570, 571, 572, or 573 amino acid residues. In other 
words, some embodiments comprise a BChE polypeptide 
fragments having about 1 to about 139 amino acid residues 10 
deleted compared to the wild type BChE polypeptide. In 
some embodiments the BChE polypeptide fragment has 
amino acid residues deleted from the N-terminus of the 
polypeptide, the C-terminus of the polypeptide, or a com-
bination thereof. In some embodiments the BChE polypep- 15 
tide fragment comprises at least amino acids 42-476. In 
other embodiments the BChE polypeptide fragment com-
prises amino acids 1-529, 1-530, 1-531, 1-532, 1-533, 1-534, 
1-135, or 1-536. 
In this regard, the terms "polypeptide fragment" or "frag- 20 
ment", when used in reference to a reference polypeptide, 
refers to a polypeptide in which amino acid residues are 
deleted as compared to the reference polypeptide itself, but 
where the remaining amino acid sequence is usually iden-
tical to the corresponding positions in the reference poly- 25 
peptide. As mentioned above, such deletions can occur at the 
amino-terminus of the reference polypeptide, the carboxy-
terminus of the reference polypeptide, or both terminuses. A 
fragment can also be a "functional fragment," in which case 
the fragment retains some or all of the activity of the 30 
reference polypeptide as described herein. For example, in 
some embodiments a functional fragment of a particular 
BChE polypeptide variant can retain some or all of the 
cocaine hydrolysis activity, i.e., the catalytic efficiency for 
( - )-cocaine, of the particular BChE polypeptide variant. In 35 
this regard, the term "BChE polypeptide variant" is inclu-
sive of functional fragments of the BChE polypeptide vari-
ant. The term "BChE polypeptide variant" is inclusive of 
functional fragments wherein one or more residues from 1 to 
41 and/or one or more residues from 477 to 574 are 40 
truncated relative to the full-length BChE polypeptide vari-
ant. See Brimijoin, S. et al., Neuropsychopharmacology 
2008, 33, 2715-2725. 
In some embodiments, the isolated polypeptide comprises 
a second polypeptide variant and/or fragment thereof. For 45 
example, the 233 amino acid sequence shown as SEQ ID 
NO: 2 is the wild type second polypeptide, and this wild type 
polypeptide can have one or more amino acid substitutions 
selected from AlQ, AlV, C6S, C12S, C15S, P24S, T36Q, 
M38Y, M38W, M38F, I39A, 540T, T42D, T42E, T42Q, 50 
P43I, E58Q, E69Q, E80Q, T93Q, V94P, V94T, L95P, Q97I, 
Q97S, D98N, NlOlD, D142E, L144M, A164V, E166A, 
G171D, G171R, Q172T, Q172P, P173R, N175P, N175S, 
M214L, N220A, N220Y, N220H, N220F, Y222H, and 
Y222I. In some embodiments, the variant comprises one, 55 
two, three, four, five, six, seven, eight, nine or ten of these 
amino acid substitutions relative to SEQ ID NO: 2. In some 
embodiments, isolated polypeptides comprising second 
polypeptide variants exhibit an increased half-life over iso-
lated polypeptides comprising a wild type second polypep- 60 
tide. 
In some embodiments, the second polypeptide is a frag-
ment of a wild type second polypeptide. In some embodi-
ments the second polypeptide can comprise at least about 
217,218,219,220,221,222,223,224,225,226,227,228, 65 
229, 230, 231, or 232 amino acid residues. In other words, 
some embodiments comprise second polypeptides frag-
16 
ments having about 1 to about 16 amino acid residues 
deleted compared to the wild type second polypeptide. In 
some embodiments the second polypeptide fragment has 
amino acid residues deleted from the N-terminus of the 
polypeptide, the C-terminus of the polypeptide, or a com-
bination thereof. 
Embodiments of the isolated polypeptide can comprise a 
BChE polypeptide, or a variant and/or fragment thereof, and 
a second polypeptide, or a variant and/or fragment thereof, 
that are in any order relative to each other. Specifically, in 
some embodiments the isolated polypeptide comprises, from 
the N-terminus to the C-terminus, a BChE polypeptide and 
a second polypeptide. In other embodiments the isolated 
polypeptide comprises, from the N-terminus to the C-termi-
nus, a second polypeptide and a BChE polypeptide. 
Some embodiments of an isolated polypeptide further 
comprise a linker disposed between the BChE polypeptide 
and the second polypeptide. In some embodiments the linker 
comprises a sequence of about 1 to about 7 amino acid 
residues. In some embodiments the linker comprises one or 
more glycine residue in sequence with a terminal serine 
(e.g., GGGGGGS (SEQ ID NO: 4)). 
Exemplary isolated polypeptides include those listed in 
Table 1 below. 
TABLE 1 
BChE Second Second Isolated 
Poly- Poly- Poly- Poly- t112 
BChE peptide BChE peptide peptide peptide (h) 
vari- SEQ ID Amino SEQ ID Amino SEQ ID in 
ant NO: Acids Linker NO Acids NO: rats 
A SEQ ID 1-529 GGGGGGS SEQ ID 17-233 SEQ ID 24 
NO 50 NO:4 NO 147 
A SEQ ID 1-529 No Linker SEQ ID 1-233 SEQ ID 83 
NO 50 NO2 NO 148 
A SEQ ID 1-574 GGGGGGS SEQ ID 1-233 SEQ ID 19 
NO 46 NO 6 NO 149 
A SEQ ID 1-574 No Linker SEQ ID 1-233 SEQ ID 24 
NO 46 NO 6 NO 150 
A SEQ ID 1-529 GGGGGGS SEQ ID 1-233 SEQ ID 48 
NO 50 NO 6 NO 151 
A SEQ ID 1-529 No Linker SEQ ID 1-233 SEQ ID 110 
NO 50 NO 6 NO 152 
A SEQ ID 1-529 No Linker SEQ ID 1-233 SEQ ID 85 
NO 50 NO 8 NO 153 
A SEQ ID 1-529 No Linker SEQ ID 1-233 SEQ ID 82 
NO 50 NO 10 NO 154 
A SEQ ID 1-530 No Linker SEQ ID 1-233 SEQ ID 131 
NO 135 NO 6 NO 155 
A SEQ ID 1-531 No Linker SEQ ID 1-233 SEQ ID 27 
NO 48 NO 6 NO 156 
A SEQ ID 1-532 No Linker SEQ ID 1-233 SEQ ID 93 
NO 136 NO 6 NO 157 
A SEQ ID 1-533 No Linker SEQ ID 1-233 SEQ ID 146 
NO 137 NO 6 NO 158 
A SEQ ID 1-534 No Linker SEQ ID 1-233 SEQ ID 115 
NO 138 NO 6 NO 159 
A SEQ ID 1-535 No Linker SEQ ID 1-233 SEQ ID 157 
NO 139 NO 6 NO 160 
A SEQ ID 1-536 No Linker SEQ ID 1-233 SEQ ID 141 
NO 140 NO 6 NO 161 
A SEQ ID 1-537 No Linker SEQ ID 1-233 SEQ ID 122 
NO 141 NO 6 NO 162 
A SEQ ID 1-538 No Linker SEQ ID 1-233 SEQ ID 106 
NO 142 NO 6 NO 163 
A SEQ ID 1-539 No Linker SEQ ID 1-233 SEQ ID 100 
NO 143 NO 6 NO 164 
A SEQ ID 1-540 No Linker SEQ ID 1-233 SEQ ID 121 
NO 144 NO 6 NO 165 
A SEQ ID 1-529 No Linker SEQ ID 1-233 SEQ ID 174 
NO 50 NO 12 NO 166 
A SEQ ID 1-529 No Linker SEQ ID 1-233 SEQ ID 143 
NO 50 NO 14 NO 167 
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TABLE I-continued 
BChE Second Second Isolated 
Poly- Poly- Poly- Poly-
BChE peptide BChE peptide peptide peptide 
vari- SEQ ID Amino SEQ ID Amino 
ant NO: Acids Linker NO Acids 
A SEQ ID 1-529 No Linker SEQ ID 1-233 
NO 50 NO 16 
A SEQ ID 1-529 No Linker SEQ ID 1-233 
NO 50 NO 18 
A SEQ ID 1-533 No Linker SEQ ID 1-233 
NO 137 NO 18 
A SEQ ID 1-536 No Linker SEQ ID 1-233 
NO 140 NO 18 
A SEQ ID 1-529 No Linker SEQ ID 1-233 
NO 50 NO 20 
A SEQ ID 1-529 No Linker SEQ ID 1-233 
NO 50 NO 22 
A SEQ ID 1-529 No Linker SEQ ID 1-233 
NO 50 NO 24 
A SEQ ID 1-533 No Linker SEQ ID 1-233 
NO 137 NO 24 
A SEQ ID 1-536 No Linker SEQ ID 1-233 
NO 140 NO 24 
B SEQ ID 1-529 No Linker SEQ ID 1-233 
NO 145 NO 6 
B SEQ ID 1-536 No Linker SEQ ID 1-233 
NO 146 NO 18 
B SEQ ID 1-529 No Linker SEQ ID 1-233 
NO 62 NO 12 
B SEQ ID 1-529 No Linker SEQ ID 1-233 
NO 62 NO 18 
C SEQ ID 1-529 No Linker SEQ ID 1-233 
NO 58 NO 12 
C SEQ ID 1-529 No Linker SEQ ID 1-233 
NO 58 NO 18 
A represents the A199S/F227A/S287G/A328WN332G variant. 
B refers to the A199SIF227 AIP285Q/S287G/A328W/Y332G variant. 
















































The presently-disclosed subject matter also includes 
nucleic acid molecules that encode an isolated polypeptide. 
In some embodiments the nucleic acid molecule comprises 
a nucleic acid molecule encoding a BChE polypeptide 
variant and/or fragment (e.g., SEQ ID NOS: 27, 29, 31, 33, 
35,37,39,41,43,45,47,49,51, 53,55,57,59, 61,63,65, 
67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 
99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 
123, 125, 127, 129, 131, or 133). Alternatively or addition-
ally, in some embodiments the nucleic acid molecule com-
prises a nucleic acid molecule encoding a second polypep-
tide variant and/or fragment (e.g., SEQ ID NOS: 5, 7, 9, 11, 
13, 15, 17, 19, 21, 23). 
The terms "nucleotide," "polynucleotide," "nucleic acid," 







deoxyribonucleic acid (DNA) and ribonucleic acid, and 
therefore the term nucleotide specifically includes comple-
mentary DNA as used herein. 
The isolated polypeptide can be formulated in a pharma-
ceutical composition along with a suitable pharmaceutical 
carrier known to one skilled in the art. As described above, 
the isolated polypeptide that is included in the pharmaceu-
tical composition can comprise a BChE polypeptide, includ-
ing variants and/or fragments thereof, and a second poly-
peptide, including variants and/or fragments thereof. In 
some embodiments, the isolated polypeptide formulated in a 
pharmaceutical composition can further comprise a linker 
disposed between the BChE polypeptide and the second 
polypeptide. 
The term "pharmaceutically acceptable carrier" refers to 
sterile aqueous or nonaqueous solutions, dispersions, sus-
pensions or emulsions, as well as sterile powders for recon-
stitution into sterile injectable solutions or dispersions just 
prior to use. Proper fluidity can be maintained, for example, 
by the use of coating materials such as lecithin, by the 
maintenance of the required particle size in the case of 
dispersions and by the use of surfactants. These composi-
tions can also contain adjuvants such as preservatives, 
wetting agents, emulsifying agents and dispersing agents. 
Prevention of the action of microorganisms can be ensured 
by the inclusion of various antibacterial and antifungal 
agents such as paraben, chlorobutanol, phenol, sorbic acid 
and the like. It can also be desirable to include isotonic 
agents such as sugars, sodium chloride and the like. Pro-
30 longed absorption of the injectable pharmaceutical form can 
be brought about by the inclusion of agents, such as alumi-
num monostearate and gelatin, which delay absorption. 
Injectable depot forms are made by forming microencapsule 
matrices of the drug in biodegradable polymers such as 
35 polylactide-polyglycolide, poly(orthoesters) and poly(anhy-
drides). Depending upon the ratio of drug to polymer and the 
nature of the particular polymer employed, the rate of drug 
release can be controlled. Depot injectable formulations are 
also prepared by entrapping the drug in liposomes or micro-
40 emulsions which are compatible with body tissues. The 
injectable formulations can be sterilized, for example, by 
filtration through a bacterial-retaining filter or by incorpo-
rating sterilizing agents in the form of sterile solid compo-
sitions which can be dissolved or dispersed in sterile water 
45 or other sterile injectable media just prior to use. Suitable 
inert carriers can include sugars such as lactose. 
Suitable formulations include aqueous and non-aqueous 
sterile injection solutions that can contain antioxidants, 
buffers, bacteriostats, bactericidal antibiotics and solutes 
50 that render the formulation isotonic with the bodily fluids of 
the intended recipient; and aqueous and non-aqueous sterile 
suspensions, which can include suspending agents and 
thickening agents. 
or ribonucleotides and polymers thereof in either single or 
double stranded form. Unless specifically limited, the term 
encompasses nucleic acids containing known analogues of 
natural nucleotides that have similar binding properties as 
the reference nucleic acid and are metabolized in a manner 
similar to naturally occurring nucleotides. Unless otherwise 
indicated, a particular nucleic acid sequence also implicitly 
encompasses conservatively modified versions thereof ( e.g., 
degenerate codon substitutions) and complementary 
sequences and as well as the sequence explicitly indicated. 60 
Specifically, degenerate codon substitutions can be achieved 
The compositions can take such forms as suspensions, 
55 solutions or emulsions in oily or aqueous vehicles, and can 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Alternatively, the active ingredient 
can be in powder form for constitution with a suitable 
vehicle, e.g., sterile pyrogen-free water, before use. 
The formulations can be presented in unit-dose or multi-
dose containers, for example sealed ampoules and vials, and 
can be stored in a frozen or freeze-dried (lyophilized) 
condition requiring only the addition of sterile liquid carrier 
immediately prior to use. 
by generating sequences in which the third position of one 
or more selected ( or all) codons is substituted with mixed 
base and/or deoxyinosine residues (Batzer et al. (1991) 
Nucleic Acid Res 19:5081; Ohtsuka et al. (1985) J Biol 65 
Chem 260:2605 2608; Rossolini et al. (1994) Mo! Cell 
Probes 8:91 98). Thus, the term nucleotide includes both 
For oral administration, the compositions can take the 
form of, for example, tablets or capsules prepared by a 
conventional technique with pharmaceutically acceptable 
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tering to an individual (subject) an effective amount of the 
present isolated polypeptides ( e.g., a fusion polypeptide 
comprising a BChE polypeptide and a second polypeptide, 
or variants and/or fragments of either) to lower blood 
excipients such as binding agents ( e.g., pregelatinized maize 
starch, polyvinylpyrrolidone or hydroxypropyl methylcellu-
lose ); fillers ( e.g., lactose, microcrystalline cellulose or 
calcium hydrogen phosphate); lubricants (e.g., magnesium 
stearate, talc or silica); disintegrants ( e.g., potato starch or 
sodium starch glycollate ); or wetting agents ( e.g., sodium 
lauryl sulphate). The tablets can be coated by methods 
known in the art. 
5 cocaine concentration. The isolated polypeptide can be 
administered in the form of a pharmaceutical composition in 
which the isolated polypeptide is included with a suitable 
pharmaceutical carrier. Treatment of a cocaine-induced con-
dition using one of the aforementioned isolated polypeptides Liquid preparations for oral administration can take the 
form of, for example, solutions, syrups or suspensions, or 
they can be presented as a dry product for constitution with 
water or other suitable vehicle before use. Such liquid 
preparations can be prepared by conventional techniques 
with pharmaceutically acceptable additives such as suspend-
ing agents (e.g., sorbitol syrup, cellulose derivatives or 15 
hydrogenated edible fats); emulsifying agents (e.g. lecithin 
10 can be in a manner that will be understood by those skilled 
in the art. 
In this regard, the term "administering" refers to any 
method of providing a isolated polypepride and/or pharma-
ceutical composition thereof to a subject. Such methods are 
well known to those skilled in the art and include, but are not 
limited to, oral administration, transdermal administration, 
administration by inhalation, nasal administration, topical 
administration, intravaginal administration, ophthalmic 
administration, intraaural administration, intracerebral 
administration, rectal administration, and parenteral admin-
istration, including injectable such as intravenous adminis-
tration, intra-arterial administration, intramuscular adminis-
tration, subcutaneous administration, intravitreous 
administration, intracameral (into anterior chamber) admin-
or acacia); non-aqueous vehicles (e.g., almond oil, oily 
esters, ethyl alcohol or fractionated vegetable oils); and 
preservatives ( e.g., methyl or propyl-p-hydroxybenzoates or 
sorbic acid). The preparations can also contain buffer salts, 20 
flavoring, coloring and sweetening agents as appropriate. 
Preparations for oral administration can be suitably formu-
lated to give controlled release of the active compound. For 
buccal administration the compositions can take the form of 
tablets or lozenges formulated in conventional manner. 25 istration, subretinal administration, sub-Tenon's administra-
tion, peribulbar administration, and the like. Administration 
can be continuous or intermittent. In various aspects, a 
preparation can be administered therapeutically; that is, 
The compositions can also be formulated as a preparation 
for implantation or injection. Thus, for example, the com-
pounds can be formulated with suitable polymeric or hydro-
phobic materials (e.g., as an emulsion in an acceptable oil) 
or ion exchange resins, or as sparingly soluble derivatives 30 
(e.g., as a sparingly soluble salt). The compounds can also 
be formulated in rectal compositions, creams or lotions, or 
transdermal patches. 
The present isolated polypeptides, whether or not they are 
in a pharmaceutical composition, include pharmaceutically 35 
acceptable salts thereof. Thus, any reference to an isolated 
polypeptides herein can include pharmaceutically accept-
able salts of the isolated polypeptide. In this regard, the term 
"pharmaceutically acceptable salts" refers to salts prepared 
from pharmaceutically acceptable non-toxic bases or acids. 40 
When the compound of the present invention is acidic, its 
corresponding salt can be conveniently prepared from phar-
maceutically acceptable non-toxic bases, including inor-
ganic bases and organic bases. Salts derived from such 
inorganic bases include aluminum, ammonium, calcium, 45 
copper (-ic and -ous), ferric, ferrous, lithium, magnesium, 
manganese (-ic and -ous), potassium, sodium, zinc and the 
like salts. Others include the anmionium, calcium, magne-
sium, potassium and sodium salts. Salts derived from phar-
maceutically acceptable organic non-toxic bases include 50 
salts of primary, secondary, and tertiary amines, as well as 
cyclic amines and substituted amines such as naturally 
occurring and synthesized substituted amines. Other phar-
maceutically acceptable organic non-toxic bases from which 
salts can be formed include ion exchange resins such as, for 55 
example, arginine, betaine, caffeine, choline, N,N'-dibenzy-
lethylenediamine, diethylamine, 2-diethylamino ethanol, 
2-dimethylaminoethanol, ethanolamine, ethylenediamine, 
N-ethylmorpholine, N-ethylpiperidine, glucamine, glu-
cosamine, histidine, hydrabamine, isopropylamine, lysine, 60 
methylglucamine, morpholine, piperazine, piperidine, 
polyamine resins, procaine, purines, theobromine, triethyl-
amine, trimethylamine, tripropylamine, tromethamine and 
the like. 
Additionally, the presently-disclosed subject matter 65 
includes methods for treating a cocaine-induced condition. 
In some embodiments treatment methods include adminis-
administered to treat an existing cocaine-induced condition 
(e.g., cocaine overdose or cocaine addiction). In further 
various aspects, a preparation can be administered prophy-
lactically; that is, administered for prevention of a cocaine-
induced condition. 
The dose for administration of an isolated polypeptide or 
pharmaceutical composition in accordance with the pres-
ently-described subject matter can be an amount which will 
be effective in lowering (-)-cocaine concentration in a 
patient's bloodstream. One would recognize that this 
amount will vary greatly depending on the nature of cocaine 
consumed, e.g., injected or inhaled and the condition of a 
patient. Furthermore, in some embodiments the isolated 
polypeptide should effectively lower (-)-cocaine concentra-
tion in blood over a predetermined time period, including 
time period of about 5 days, 10 days, 15 days, 20 days, 25 
days, 30 days, 35 days, 40 days, 45 days, 50 days, 55 days, 
or 60 days. In some embodiments the isolated polypeptide 
has a biological half-life that is shorter than a predetermined 
time period in which the isolated polypeptide can effectively 
lower (-)-cocaine concentration. For instance, in some 
embodiments the isolated polypeptide can have a biological 
half-life of about 4 days, about 10 days, about 15 days, 20 
days, 25 days, 30 days, 35 days, or 40 days. 
Thus, an "effective amount" of isolated polypeptide or 
pharmaceutical composition to be used in accordance with 
the presently-disclosed subject matter is intended to mean a 
nontoxic but sufficient amount of the isolated polypeptide or 
pharmaceutical composition thereof, such that the desired 
prophylactic or therapeutic effect is produced. The exact 
amount of the isolated polypeptide or pharmaceutical com-
position that is required will vary from subject to subject, 
depending on the species, age, and general condition of the 
subject, the severity of the condition being treated, the 
particular carrier or adjuvant being used and its mode of 
administration, and the like. Similarly, the dosing regimen 
should also be adjusted to suit the individual to whom the 
composition is administered and will once again vary with 
age, weight, metabolism, etc. of the individual. Accordingly, 
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the "effective amount" of any particular isolated polypeptide 
or pharmaceutical composition thereof will vary based on 
the particular circumstances, and an appropriate effective 
amount may be determined in each case of application by 
one of ordinary skill in the art using only routine experi- 5 
1 xl 05 /mL and cultured steadily in freestyle CHO expression 
medium with 1 % FBS. Cells began to attach to plate soon 
after the change of culture condition. Lentivirus was then 
added to infect cells for 1 day with two intermittent additions 
of the virus. Infected cells were suspended by 0.05% 
trypsin-EDTA and seeded at 2 to 10 cells/well in 96-well mentation. 
The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 
The following examples may include compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 
related to the presently-disclosed subject matter. 
EXAMPLES 
Embodiments of an isolated polypeptide comprising a 
BChE polypeptide and a second polypeptide, or variants 
and/or fragments thereof, were made and studied using the 
following experimental procedure. For each isolated poly-
peptide conceived, following site-directed mutagenesis, the 
isolated polypeptides were produced in a small scale for in 
vitro assays and pharmacokinetic assay in rats through 
transient transfection of the corresponding cDNA. Stable 
cell lines were produced for certain isolated polypeptides in 
large scale for more in vivo studies. One particular isolated 
polypeptide synthesized in this Example comprised a second 
polypeptide represented by SEQ ID NO: 6, a BChE poly-
peptide represented by SEQ ID NO: 48, and no linker 
there between. 
plate in 1 % FBS free-style medium again to culture for 
another 14 to 21 days without changing medium and shaking 
until single clones clearly appeared. Single-clone cell lines 
10 from 96-well plates were chosen to culture in 48-well plates, 
then 12-well plates and 6-well plates in 1 % FBS freestyle 
CHO expression medium. High expression single-clone cell 
lines were screened and selected by determining BChE 
activity in medium. Selected cells were then changed back 
15 to suspension culture and the culture volume increased from 
6-well plate to 125 ml flask and a series of larger flasks and 
finally 2-L flask. Culture medium was changed every 2 to 3 
days and collected to store at 4° C. in sterilized bottles for 
protein purification. Each liter of culture medium was 
20 expected to contain about 7 to 20 mg of the isolated 
polypeptide. Thus, -20 to 100 L culture medium was 
collected for each isolated polypeptide, depending on the 
need and expression. A 40 L Sterilizable-in-Place CelliGen 
510 Bioreactor (New Brunswick, N.J.) was used for the 
25 larger-scale production of some of the promising isolated 
polypeptides. The secreted isolated polypeptide in the col-
lected culture medium was purified using the same Protein 
A affinity chromatography as mentioned above. 
Active-Site Titration. 
Site-Directed Mutagenesis and Isolated Polypeptide Syn- 30 
thesis. 
The active-site concentration of the purified isolated poly-
peptide was determined by using a standard protocol 
through titration using an irreversible BChE inhibitor, di-
isopropylfluorophosphate (DFP). For the active-site titra-
tion, each enzyme was incubated for 24 h with varying 
Briefly, site-directed mutagenesis of the isolated polypep-
tide' s cDNA was performed by using the QuikChange 
method. Further mutations were generated from the cDNA 
in a pCMV-MCS expression plasmid. The isolated polypep-
tides were expressed in Chinese hamster ovary (CHO)-S 
cells using the freestyle CHO expression medium (Catalog 
#12651022; Invitrogen; Grand Island, N.Y.). The secreted 
isolated polypeptide in the collected culture medium was 
purified using affinity chromatography on Protein A sephar-
ose with appropriate pH adjustment. 
Generation of Recombinant Lentivirus Expressing Iso-
lated Polypeptide. 
cDNAs of the isolated polypeptide in lentivirus plasmids 
were constructed in pCSC-SP-PW vector at ApaI and Xhol 
I sites by PCR with the isolated polypeptides in pCMV-MCS 
plasmids as templates. The sequences of constructs were 
confirmed by DNA sequencing. Starting from one isolated 
polypeptide, the other isolated polypeptides, having muta-
tions and/or fragments of either BChE or the second poly-
peptide, were generated by the QuickChange method. The 
lentiviruses encoding isolated polypeptides were then pre-
pared. 
Scaling Up Isolated Polypeptide Production. 
Large-scale preparation of an isolated polypeptide was 
achieved first by infecting CHO-S cells with lentivirus 
followed by resuspending attached CHO-S cells in suspen-
sion culture in the freestyle CHO expression medium. See, 
e.g., Xue, L.; Hou, S.; Tong, M.; Fang, L.; Chen, X.; Jin, Z.; 
Tai, H.-H.; Zheng, F.; Zhan, C.-G. "Preparation and in vivo 
characterization of a cocaine hydrolase engineered from 
human butyrylcholinesterase for metabolizing cocaine", 
Biochem. J. 2013, 453, 447-454, which is incorporated 
herein by this reference. CHO-S cells were routinely sus-
pension cultured in serum-free medium according to manu-
facturer's instruction at 8% CO2 , 37° C. on orbit shaker at 
125 rpm. The day before infection, cells were loaded at 
35 concentrations of DFP, followed by the measurement of the 
residual BChE activity. In this way, the residual BChE 
activity was reduced linearly with increasing sub-stoichio-
metric amounts of DFP and, thus, the active-site concentra-
tion of the enzyme could be calculated by the intercept with 
40 the axis representing the DFP concentration. 
In Vitro Activity Assay. 
The catalytic activity of the isolated polypeptide against 
(-)-cocaine was determined by using the sensitive radio-
metric assay with [3H]-( - )-cocaine labeled on its benzene 
45 ring. The assay is based on toluene extraction of product 
[
3 H]-benzoic acid. 
In Vivo Assay. 
The pharmacokinetics, in vivo potency, and immunoge-
nicity in rats was determined for each isolated polypeptide. 
50 Rats were anesthetized and given a single dose (0.1 or 1 
mg/kg) of isolated polypeptide or PBS buffer (the negative 
control) via the tail vein. After the isolated polypeptide 
injection, blood samples ( <50 µl) were collected from 
saphenous vein at 2 min, 15 min, 30 min, 1 hr, 2 hr, 3 hr, 5 
55 hr, 8 hr, 12 hr, 1 day and every day within 15 days. The 
isolated polypeptide's activity in plasma was determined 
using the same radiometric [3 H]-(-)-cocaine assay as used 
for the above in vitro enzyme activity assay. 
To characterize the in vivo catalytic activity of each 
60 isolated polypeptide against ( - )-cocaine at a given time 
point (10 min, 5 hr, 1 day, 3 days, 7 days, and 14 days) after 
the isolated polypeptide injection, the anesthetized rats were 
given 5.6 mg/kg (-)-cocaine intravenously (i.v.). At 1 min, 
2 min, 5 min, 10 min, 20 min, 30 min, 60 min, 90 min, and 
65 120 min after the (-)-cocaine injection, a blood sample was 
collected from saphenous vein into heparin-treated tubes 
containing DFP. DFP was used to irreversibly inhibit the 
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esterases (including injected isolated polypeptide, native 
BChE, and carboxylesterases) in plasma to terminate the 
enzymatic cocaine hydrolysis. The blood samples were 
centrifuged to obtain plasma which contains both (-)-co-
caine (the drug) and its metabolites that could be analyzed 5 
by using a Waters Breeze HPLC system in the PI's lab. The 
time-dependent concentrations of cocaine and metabolites 
were fitted to the standard kinetic equation of the enzymatic 
( - )-cocaine hydrolysis along with an elimination model in 
order to determine the kinetic parameters (V max and KM) of 
isolated polypeptide against (-)-cocaine in plasma. 
To calculate the activity half life, the known formula for 
the time (t)-dependence of [E] was utilized, which follows 
a double exponential equation which accounts for both the 
enzyme distribution process (the fast phase, associated with 
a 1) and elimination process (the slow phase, associated with 
a 2). The biological half-life refers to the elimination pro-
cess. 
[E]~A exp(-a1t)+B exp(-a2t) 
As shown in FIG. 1, the biological half-life of an isolated 
polypeptide comprising a second polypeptide represented by 
SEQ ID NO: 6, a BChE polypeptide represented by SEQ ID 
NO: 48, and no linker therebetween in rats was about 110 hr. 
While the terms used herein are believed to be well 
understood by one of ordinary skill in the art, the definitions 
set forth herein are provided to facilitate explanation of the 
presently-disclosed subject matter. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a protein" includes a plurality of such proteins, and 
so forth. 
Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 









disclosed subject matter. 50 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±50%, in some embodiments 
±40%, in some embodiments ±30%, in some embodiments 55 
±20%, in some embodiments ± 10%, in some embodiments 
±5%, in some embodiments ±1 %, in some embodiments 
±0.5%, and in some embodiments ±0.1 % from the specified 
amount, as such variations are appropriate to perform the 
disclosed method. 60 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 65 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
24 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
SEQUENCE LISTING 
Fe Wild Type 
SEQ ID NO, 1 
GCA GAG CCT AAG TCC TGC GAC AAA ACT CAC ACA TGC 
CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG 
TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC 
CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG 
GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG 
TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT 
GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC 
ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC 
CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG 
GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA 
ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA 
CAG GTG TAC ACC CTG CCC CCA TCC CGG GAC GAG CTG 
ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA 
GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG 
AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG 
CCT CCC GTG CTG GAC TCC GAC GGC TCC TTC TTC CTC 
TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG 
CAG GGG AAC GTC TTC TCA TGC TCC GTG ATG CAC GAG 
GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC 
CTG TCT CCG GGT AAA 
Fe Wild Type 
SEQ ID NO, 2, 
AEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS 
RTPEVTCVW DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 
TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 
SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 
Fe Wild Type Fragment 
SEQ ID NO, 3, 
GCA CCT GAA CTC CTG GGG GGA CCG TCA GTC TTC 
CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC ATG 
ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG 
US 10,772,940 Bl 
25 
-continued 
Fe Wild Type Fragment 
GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG 
TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT 
AAT GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC 
AAC AGC ACG TAC CGT GTG GTC AGC GTC CTC ACC 
GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG GAG 
TAC AAG TGC AAG GTC TCC AAC AAA GCC CTC CCA 
GCC CCC ATC GAG AAA ACC ATC TCC AAA GCC AAA 
GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG 
CCC CCA TCC CGG GAC GAG CTG ACC AAG AAC CAG 
GTC AGC CTG ACC TGC CTG GTC AAA GGC TTC TAT 
CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT 
GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT 
CCC GTG CTG GAC TCC GAC GGC TCC TTC TTC CTC 
TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG 
CAG CAG GGG AAC GTC TTC TCA TGC TCC GTG ATG 
CAC GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG 
AGC CTC TCC CTG TCT CCG GGT AAA 
Fe Wild Type Fragment 
SEQ ID NO, 4 
APEL LGGPSVFLFP PKPKDTLMIS 
RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 
QYNSTYRWS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 
TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 
SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 
Fe Mutant (Fel) 
SEQ ID NO, 5 
GTG GAG CCT AAG TCC TGC GAC AAA ACT CAC ACA 
TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG 
GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC 
AAG GAC ACC CTC ATG ATC TCC CGG ACC CCT GAG 
GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA 
GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC 
GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG 
CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG 















Fe Mutant (Fel) 
CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC 
AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC 
ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA 
CAG GTG TAC ACC CTG CCC CCA TCC CGG GAG GAG 
ATG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG 
GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG 
GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC 
TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC 
GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG 
GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC 
TCA TGC TCC GTG ATG CAC GAG GCT CTG CAC AAC 
CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG 
GGT AAA 
Fe Mutant (Fel) 
SEQ ID NO, 6 
VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS 
RTPEVTCVW DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 
TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 
SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 
Fe Mutant (Fe2) 
SEQ ID NO, 7 
GTG GAG CCT AAG TCC TGC GAC AAA ACT CAC ACA 
TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG 
GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC 
AAG GAC ACC CTC ATG ATC TCC CGG ACC CCT GAG 
GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA 
GAC CCT CAG GTC AAG TTC AAC TGG TAC GTG GAC 
GGC GTC CAG GTG CAT AAT GCC AAG ACA AAG CCG 
CGG GAG CAG CAG TAC AAC AGC ACG TAC CGT GTG 
GTC AGC GTC CTC ACC GTC CTG CAC CAG AAT TGG 
CTG GAC GGC AAG GAG TAC AAG TGC AAG GTC TCC 
AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC 
ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA 
CAG GTG TAC ACC CTG CCC CCA TCC CGG GAG GAG 
ATG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG 
US 10,772,940 Bl 
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-continued 
Fe Mutant (Fe2) 
GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG 
GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC 
TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC 
GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG 
GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC 




Fe Mutant (Fe3) 
GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC 
CTG TCT CCG GGT AAA 
Fe Mutant (Fe3) 
SEQ ID NO, 10 
QEPKSSDKTH TSPPSPAPEL LGGSSVFLFP PKPKDTLMIS 
CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG 15 
RTPEVTCVW DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 
TISKAKGQPR EPQVYTLPPS REELTKNQVS LTCLVKGFYP 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 
SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 
GGT AAA 
Fe Mutant (FC2) 
SEQ ID NO, 8 
VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS 
RTPEVTCVVV DVSHEDPQVK FNWYVDGVQV HNAKTKPREQ 
QYNSTYRWS VLTVLHQNWL DGKEYKCKVS NKALPAPIEK 
TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP 
20 
25 Fe Mutant (Fe4) 
SEQ ID NO, 11 
GTG GAG CCT AAG TCC TGC GAC AAA ACT CAC ACA TGC 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 30 
CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA CCG 
TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC 
CTC TAT ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG 
SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 
Fe Mutant (Fe3) 
SEQ ID NO, 9 
CAG GAG CCT AAG TCC TCC GAC AAA ACT CAC ACA TCC 
CCA CCG TCC CCA GCA CCT GAA CTC CTG GGG GGA TCC 
TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC 
CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG 
GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG 
TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT 
GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC 
ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC 
CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG 
GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA 
ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA 
CAG GTG TAC ACC CTG CCC CCA TCC CGG GAC GAG CTG 
ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA 
GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG 
AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG 
CCT CCC GTG CTG GAC TCC GAC GGC TCC TTC TTC CTC 
TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG 
GTG GTG GAC GTG AGC CAC GAA GAC CCT GAG GTC AAG 
35 
TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT 
GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC 
ACG TAC CGT GTG GTC AGC GTC CTC ACC GTC CTG CAC 
40 CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG 
GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA 
ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA 
45 CAG GTG TAC ACC CTG CCC CCA TCC CGG GAG GAG ATG 
ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC AAA 
GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG 
50 AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG 
CCT CCC GTG CTG GAC TCC GAC GGC TCC TTC TTC CTC 
TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG 
55 
CAG GGG AAC GTC TTC TCA TGC TCC GTG ATG CAC GAG 
60 
GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC 
CTG TCT CCG GGT AAA 
Fe Mutant (Fe4) 
SEQ ID NO, 12 
VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLYIS 
CAG GGG AAC GTC TTC TCA TGC TCC GTG ATG CAC GAG 65 
RTPEVTCVW DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 
US 10,772,940 Bl 
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-continued 
Fe Mutant (Fe4) 
QYNSTYRWS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 
TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 
SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 
Fe Mutant (Fe5) 
SEQ ID NO, 13 
GTG GAG CCT AAG TCC TGC GAC AAA ACT CAC ACA 
TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG 
GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC 
AAG GAC ACC CTC ATG ATC TCC CGG GAA CCT GAG 
GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA 
GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC 
GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG 
CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG 
GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG 
CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC 
AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC 
ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA 
CAG GTG TAC ACC CTG CCC CCA TCC CGG GAG GAG 
ATG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG 
GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG 
GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC 
TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC 
GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG 
GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC 
TCA TGC TCC GTG ATG CAC GAG GCT CTG CAC AAC 
CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG 
GGT AAA 
Fe Mutant (Fe5) 
SEQ ID NO, 14 
VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS 
REPEVTCVW DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 
QYNSTYRWS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 
TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 










Fe Mutant (Fe6) 
SEQ ID NO, 15 
GTG GAG CCT AAG TCC TGC GAC AAA ACT CAC ACA 
TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG 
GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC 
AAG GAC ACC CTC TAT ATC ACC CGG ACC CCT GAG 
GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA 
GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC 
GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG 
CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG 
GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG 
CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC 
AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC 
ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA 
CAG GTG TAC ACC CTG CCC CCA TCC CGG GAG GAG 
ATG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG 
GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG 
GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC 
TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC 
GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG 
GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC 
TCA TGC TCC GTG ATG CAC GAG GCT CTG CAC AAC 
CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG 
GGT AAA 
Fe Mutant (Fe6) 
SEQ ID NO, 16 
VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLYIT 
RTPEVTCVW DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 
50 TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 




Fe Mutant (Fe7) 
SEQ ID NO, 17 
GTG GAG CCT AAG TCC TGC GAC AAA ACT CAC ACA 
TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG 
GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC 
AAG GAC ACC CTC TAT ATC ACC CGG GAA CCT GAG 
GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA 
US 10,772,940 Bl 
31 
-continued 
Fe Mutant (Fe7) 
GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC 
GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG 
CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG 
GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG 10 
CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC 
AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC 
ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA 15 
CAG GTG TAC ACC CTG CCC CCA TCC CGG GAG GAG 
ATG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG 
GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG 
GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC 
TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC 
GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG 
GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC 
TCA TGC TCC GTG ATG CAC GAG GCT CTG CAC AAC 
CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG 
GGT AAA 
Fe Mutant (Fe7) 
SEQ ID NO, 18 
VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLYIT 
REPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 
QYNSTYRWS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 
TISKAKGQPR EPQVYTLPPS REEMTKNQVS LTCLVKGFYP 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 
SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 
Fe Mutant (Fe8) 
SEQ ID NO, 19 
CAG GAG CCT AAG TCC TCC GAC AAA ACT CAC ACA 
TCC CCA CCG TCC CCA GCA CCT GAA CTC CTG GGG 
GGA TCC TCA GTC TTC CTC TTC CCC CCA AAA CCC 
AAG GAC ACC CTC TAT ATC TCC CGG ACC CCT GAG 
GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA 
GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC 
GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG 










GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG 65 
32 
-continued 
Fe Mutant (Fe8) 
CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC 
AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC 
ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA 
CAG GTG TAC ACC CTG CCC CCA TCC CGG GAC GAG 
CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG 
GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG 
GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC 
TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC 
GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG 
GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC 
TCA TGC TCC GTG ATG CAC GAG GCT CTG CAC AAC 
CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG 
GGT AAA 
Fe Mutant (Fe8) 
SEQ ID NO, 20 
QEPKSSDKTH TSPPSPAPEL LGGSSVFLFP PKPKDTLYIS 
RTPEVTCVW DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 
TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 
SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 
Fe Mutant (Fe9) 
SEQ ID NO, 21 
CAG GAG CCT AAG TCC TCC GAC AAA ACT CAC ACA 
TCC CCA CCG TCC CCA GCA CCT GAA CTC CTG GGG 
GGA TCC TCA GTC TTC CTC TTC CCC CCA AAA CCC 
AAG GAC ACC CTC TAT ATC ACC CGG ACC CCT GAG 
GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA 
GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC 
GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG 
CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG 
GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG 
CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC 
AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC 
ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA 
CAG GTG TAC ACC CTG CCC CCA TCC CGG GAC GAG 
CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG 
US 10,772,940 Bl 
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Fe Mutant (Fe9) 
GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG 
GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC 
TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC 
34 
-continued 
Fe Mutant (Fel0) 
GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC 
TCA TGC TCC GTG ATG CAC GAG GCT CTG CAC AAC 
CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG 
GGT AAA 
GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG 10 
GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC 
TCA TGC TCC GTG ATG CAC GAG GCT CTG CAC AAC 
CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG 
GGT AAA 
Fe Mutant (Fe9) 
SEQ ID NO, 22 
QEPKSSDKTH TSPPSPAPEL LGGSSVFLFP PKPKDTLYIT 
15 
20 
Fe Mutant (Fel0) 
SEQ ID NO, 24 
QEPKSSDKTH TSPPSPAPEL LGGSSVFLFP PKPKDTLYIT 
REPEVTCVW DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 
TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 
SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 
RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 25 
QYNSTYRWS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK 
TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP 
SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK 
SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK 
Fe Mutant (Fel0) 
SEQ ID NO, 23 
CAG GAG CCT AAG TCC TCC GAC AAA ACT CAC ACA 
TCC CCA CCG TCC CCA GCA CCT GAA CTC CTG GGG 
GGA TCC TCA GTC TTC CTC TTC CCC CCA AAA CCC 
AAG GAC ACC CTC TAT ATC ACC CGG GAA CCT GAG 
GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA 
GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC 
GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG 
CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT GTG 
GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG 
CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC 
AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC 
ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA 
CAG GTG TAC ACC CTG CCC CCA TCC CGG GAC GAG 
CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG 
GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG 
GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC 




BChE Wild Type (1-574) 
SEQ ID NO, 25 
GAA GAT GAC ATC ATA ATT GCA ACA AAG AAT GGA 
AAA GTC AGA GGG ATG AAC TTG ACA GTT TTT GGT 
GGC ACG GTA ACA GCC TTT CTT GGA ATT CCC TAT 
GCA CAG CCA CCT CTT GGT AGA CTT CGA TTC AAA 
AAG CCA CAG TCT CTG ACC AAG TGG TCT GAT ATT 
TGG AAT GCC ACA AAA TAT GCA AAT TCT TGC TGT 
CAG AAC ATA GAT CAA AGT TTT CCA GGC TTC CAT 
GGA TCA GAG ATG TGG AAC CCA AAC ACT GAC CTC 
AGT GAA GAC TGT TTA TAT CTA AAT GTA TGG ATT 
45 CCA GCA CCT AAA CCA AAA AAT GCC ACT GTA TTG 
ATA TGG ATT TAT GGT GGT GGT TTT CAA ACT GGA 
ACA TCA TCT TTA CAT GTT TAT GAT GGC AAG TTT 
50 CTG GCT CGG GTT GAA AGA GTT ATT GTA GTG TCA 
ATG AAC TAT AGG GTG GGT GCC CTA GGA TTC TTA 
GCT TTG CCA GGA AAT CCT GAG GCT CCA GGG AAC 
55 
60 
GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG 65 
ATG GGT TTA TTT GAT CAA CAG TTG GCT CTT CAG 
TGG GTT CAA AAA AAT ATA GCA GCC TTT GGT GGA 
AAT CCT AAA AGT GTA ACT CTC TTT GGA GAA AGT 
GCA GGA GCA GCT TCA GTT AGC CTG CAT TTG CTT 
TCT CCT GGA AGC CAT TCA TTG TTC ACC AGA GCC 
ATT CTG CAA AGT GGT TCC TTT AAT GCT CCT TGG 
GCG GTA ACA TCT CTT TAT GAA GCT AGG AAC AGA 
ACG TTG AAC TTA GCT AAA TTG ACT GGT TGC TCT 
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-continued 
BChE Wild Type (1-574) 
AGA GAG AAT GAG ACT GAA ATA ATC AAG TGT CTT 
AGA AAT AAA GAT CCC CAA GAA ATT CTT CTG AAT 
GAA GCA TTT GTT GTC CCC TAT GGG ACT CCT TTG 
TCA GTA AAC TTT GGT CCG ACC GTG GAT GGT GAT 
TTT CTC ACT GAC ATG CCA GAC ATA TTA CTT GAA 
CTT GGA CAA TTT AAA AAA ACC CAG ATT TTG GTG 
GGT GTT AAT AAA GAT GAA GGG ACA GCT TTT TTA 
GTC TAT GGT GCT CCT GGC TTC AGC AAA GAT AAC 
AAT AGT ATC ATA ACT AGA AAA GAA TTT CAG GAA 
GGT TTA AAA ATA TTT TTT CCA GGA GTG AGT GAG 
TTT GGA AAG GAA TCC ATC CTT TTT CAT TAC ACA 
GAC TGG GTA GAT GAT CAG AGA CCT GAA AAC TAC 
CGT GAG GCC TTG GGT GAT GTT GTT GGG GAT TAT 
AAT TTC ATA TGC CCT GCC TTG GAG TTC ACC AAG 
AAG TTC TCA GAA TGG GGA AAT AAT GCC TTT TTC 
TAC TAT TTT GAA CAC CGA TCC TCC AAA CTT CCG 
TGG CCA GAA TGG ATG GGA GTG ATG CAT GGC TAT 
GAA ATT GAA TTT GTC TTT GGT TTA CCT CTG GAA 
AGA AGA GAT AAT TAC ACA AAA GCC GAG GAA ATT 
TTG AGT AGA TCC ATA GTG AAA CGG TGG GCA AAT 
TTT GCA AAA TAT GGG AAT CCA AAT GAG ACT CAG 
AAC AAT AGC ACA AGC TGG CCT GTC TTC AAA AGC 
ACT GAA CAA AAA TAT CTA ACC TTG AAT ACA GAG 
TCA ACA AGA ATA ATG ACG AAA CTA CGT GCT CAA 
CAA TGT CGA TTC TGG ACA TCA TTT TTT CCA AAA 
GTC TTG GAA ATG ACA GGA AAT ATT GAT GAA GCA 
GAA TGG GAG TGG AAA GCA GGA TTC CAT CGC TGG 
AAC AAT TAC ATG ATG GAC TGG AAA AAT CAA TTT 
AAC GAT TAC ACT AGC AAG AAA GAA AGT TGT GTG 
GGT CTC 
BChE Wild Type (1-574) 
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SEQUENCE LISTING 
The patent contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in 
electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US10772940B1). 
An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the 
fee set forth in 37 CFR 1.19(b)(3). 
What is claimed is: 
1. An isolated polypeptide having the ability to cleave 15 
3. The isolated polypeptide of claim 1, wherein the BChE 
polypeptide comprises the amino acid sequence selected 
from the group consisting of SEQ ID NOs: 46, 48, 50, 58, 
and 62. cocaine, comprising 
a butyrylcholinesterase (BChE) polypeptide having the 
ability to cleave cocaine, consisting of a variant of SEQ 
ID NO: 26 or a fragment thereof; and 
a second polypeptide, consisting of the sequence of SEQ 
ID NO: 18; 
20 
4. A pharmaceutical composition comprising: 
an isolated polypeptide of claim 1; and 
a suitable pharmaceutical carrier. 
wherein the variant of SEQ ID NO: 26 or the fragment 
thereof includes between 5 and 8 amino acid substitu- 25 
5. The pharmaceutical composition of claim 4, wherein, 
from the N-terminus to the C-terminus, the isolated poly-
peptide comprises the BChE polypeptide and the second 
polypeptide. 
6. The isolated polypeptide of claim 2, wherein the amino 
acid sequence is selected from the group of sequences 
consisting of: SEQ ID NO: 169, SEQ ID NO: 
tions; 
wherein 5 of the amino acid substitutions consist of 
A199S, F227A, S287G, A328W, and Y332G. 
2. The isolated polypeptide of claim 1, wherein the 
isolated polypeptide having the ability to cleave cocaine 
comprises an amino acid sequence selected from the group 
of sequences consisting of: SEQ ID NO: 169, SEQ ID NO: 
170, SEQ ID NO: 171, SEQ ID NO: 178, SEQ ID NO: 180, 
and SEQ ID NO: 182. 
180, and SEQ ID NO: 182. 
7. The isolated polypeptide of claim 1, wherein, in addi-
tion to A199S, F227A, S287G, A328W, and Y332G, the 
30 variant includes from 1 to 3 amino acid substitutions 
selected from the group consisting of P285A, P285E, 
P285G, P285I, P285K, P285N, P285Q, P285S, L286M, and 
E441D. 
* * * * * 
